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The importance of detecting cancer has increased over the past years as more people are affected by this
disease.  Early detection of cancer is crucial for its treatment.  The survival rate of pancreatic cancer is very
slim because it is detected at late stages.  The use of radioactive elements is of interest since they can
either emit radiations that can be used for diagnostic or therapeutic purposes.   The main goal of this
project is to incorporate a radioactive metal into a somatostatin receptor targeting analogue for diagnostic
and therapeutic purposes.  The metal incorporation into the analogue should be stable in the biological
system, to avoid any damage to the normal tissues.  Also, the radiolabeled analogue should target the
pancreatic tumors to spare the normal tissues of any radiation damage as well.   Several series of
somatostatin analogues were developed and only one metal incorporated analogue showed high binding
affinity toward pancreatic tumors.  However, the metal incorporation of this analogue was not stable under
physiological conditions (pH 7.4 and 37 Â°C).  Other analogues developed were able to hold onto the
incorporated metal under physiological conditions, however at the expense of their binding affinity to the
receptor.  Our development and characterization of these analogues will lay the foundation for future
research studies that will further develop this radiometal incorporated analogue into a clinically-relevant
detection and therapeutic option for pancreatic cancer.     
